​

Stoke Therapeutics (STOK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

STOK Stock Forecast

Stoke Therapeutics (STOK) stock forecast, based on 16 Wall Street analysts, predicts a 12-month average price target of $51.00, with a high of $58.00 and a low of $44.00. This represents a 70.45% increase from the last price of $29.92.

$5 $16 $27 $38 $49 $60 High: $58 Avg: $51 Low: $44 Last Closed Price: $29.92

STOK Stock Rating

Stoke Therapeutics stock's rating consensus is Buy, based on 16 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (81.25%), 3 Hold (18.75%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 16 0 3 13 Strong Sell Sell Hold Buy Strong Buy

STOK Price Target Upside V Benchmarks

TypeNameUpside
StockStoke Therapeutics70.45%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-211
Avg Price Target-$51.00$42.91
Last Closing Price$29.92$29.92$29.92
Upside/Downside-70.45%43.42%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26212---14
Aug, 26112---13
Jul, 26111---12
Jun, 26111---12
May, 26111---12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 04, 2026Sumant KulkarniCanaccord Genuity$58.00$29.5696.21%93.85%
Jul 13, 2026Kevin StrangGoldman Sachs$44.00$31.3840.22%47.06%
Feb 23, 2026Wolfe Research$40.00$36.2310.41%33.69%
Feb 05, 2026Yatin SunejaGuggenheim$60.00$32.0087.50%100.53%
Jan 12, 2026Wedbush$36.00$28.1427.93%20.32%
Jan 05, 2026Canaccord Genuity$36.00$30.9016.50%20.32%
Jan 05, 2026Keay NakaeLoop Capital Markets$35.00$30.9013.27%16.98%
Dec 16, 2025Andrew FeinH.C. Wainwright$50.00$32.9051.98%67.11%
Dec 15, 2025UBS$50.00$32.8252.35%67.11%
Nov 05, 2025Canaccord Genuity$28.00$21.4230.72%-6.42%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 10, 2026Goldman SachsBuyBuyhold
Jul 13, 2026Goldman SachsBuyinitialise
Feb 23, 2026Wolfe ResearchOutperforminitialise
Feb 05, 2026GuggenheimBuyinitialise
Jan 12, 2026WedbushOutperformOutperformhold
Dec 15, 2025H.C. WainwrightBuyBuyhold
Oct 10, 2025NeedhamBuyBuyhold
Aug 18, 2025BTIGBuyBuyhold
Sep 11, 2024Cowen & Co.BuyBuyhold
Sep 11, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.60$-2.38$-1.65$-0.12---
Avg Forecast$-2.66$-2.38$-2.03$-2.37$-2.55$-2.07$-1.66
High Forecast$-1.74$-2.26$-2.00$-2.04$-2.06$-0.17$-0.64
Low Forecast$-3.15$-2.48$-2.11$-2.77$-3.20$-3.40$-2.52
Surprise %-2.26%--18.72%-94.94%---

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.40M$8.78M$36.55M$184.42M---
Avg Forecast$11.70M$9.53M$17.42M$20.36M$23.29M$69.31M$108.62M
High Forecast$13.36M$10.87M$18.30M$28.57M$32.69M$97.28M$152.44M
Low Forecast$8.59M$7.83M$15.30M$10.71M$12.26M$36.48M$57.17M
Surprise %6.05%-7.82%109.87%805.87%---

Net Income Forecast

$-150M $-120M $-90M $-60M $-30M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-101.07M$-104.70M$-88.98M$-6.88M---
Avg Forecast$-117.09M$-104.70M$-90.36M$-105.69M$-115.76M$-78.53M$-72.81M
High Forecast$-76.69M$-99.54M$-87.95M$-89.73M$-90.62M$-7.48M$-27.98M
Low Forecast$-138.67M$-109.24M$-92.78M$-121.66M$-140.91M$-149.58M$-111.01M
Surprise %-13.68%--1.53%-93.49%---

STOK Forecast FAQ

Is Stoke Therapeutics stock a buy?

Stoke Therapeutics stock has a consensus rating of Buy, based on 16 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Stoke Therapeutics is a favorable investment for most analysts.

What is Stoke Therapeutics's price target?

Stoke Therapeutics's price target, set by 16 Wall Street analysts, averages $51 over the next 12 months. The price target range spans from $44 at the low end to $58 at the high end, suggesting a potential 70.45% change from the previous closing price of $29.92.

How does Stoke Therapeutics stock forecast compare to its benchmarks?

Stoke Therapeutics's stock forecast shows a 70.45% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Stoke Therapeutics over the past three months?

  • September 2026: 14.29% Strong Buy, 85.71% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 7.69% Strong Buy, 92.31% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Stoke Therapeutics’s EPS forecast?

Stoke Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.55, marking a 2025.00% increase from the reported $-0.12 in 2025. Estimates for the following years are $-2.07 in 2027, and $-1.66 in 2028.

What is Stoke Therapeutics’s revenue forecast?

Stoke Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $23.29M, reflecting a -87.37% decrease from the reported $184.42M in 2025. The forecast for 2027 is $69.32M, and $108.62M for 2028.

What is Stoke Therapeutics’s net income forecast?

Stoke Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-116M, representing an 1581.39% increase from the reported $-6.885M in 2025. Projections indicate $-78.531M in 2027, and $-72.811M in 2028.